An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Trial Profile

An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Adverse reactions; Registrational
  • Sponsors Ocular Technologies
  • Most Recent Events

    • 18 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
    • 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top